Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S (2024)
Publication Type: Journal article
Publication year: 2024
Journal
Book Volume: 30
Pages Range: 746-756
Journal Issue: 5
DOI: 10.1093/ibd/izad138
Abstract
BACKGROUND: The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs antitumor necrosis factor (anti-TNF) in biologic-naïve Crohn's disease (CD) patients. METHODS: Between 2017 and 2020, 557 CD patients starting therapy with VEDO or anti-TNF were consecutively enrolled in 45 IBD centers across Germany. Per study protocol, the analysis excluded biologic-experienced patients and those with a missing Harvey-Bradshaw Index score, resulting in a final sample of 327 biologic-naïve CD patients. Clinical remission was measured using the Harvey-Bradshaw Index at the end of induction therapy and after 1 and 2 years. Switching to a different therapy was considered an outcome failure. Propensity score adjustment with inverse probability of treatment weighting was used to correct for confounding. RESULTS: The effectiveness of both VEDO (n = 86) and anti-TNF (n = 241) was remarkably high for induction treatment, but VEDO performed significantly less well than anti-TNF (clinical remission: 56.3% vs 73.9%, P < .05). In contrast, clinical remission after 2 years was significantly better for VEDO compared with anti-TNF (74.2% vs 44.7%; P < .05; odds ratio, 0.45; 95% CI, 0.22-0.94). Remarkably, only 17% of patients switched from VEDO to another biologic vs 44% who received anti-TNF. CONCLUSIONS: The results of this prospective, 2-year, real-world evidence study suggest that the choice of VEDO led to higher remission rates after 2 years compared with anti-TNF. This could support the role of VEDO as a first-line biologic therapy in CD.
Authors with CRIS profile
Raja Atreya
Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)
Involved external institutions
Competence Network IBD
Germany (DE)
Zentrum für Gastroenterologie Saar MVZ GmbH
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Media Seasons - Steffen Kleinke & Ronny Burkersroda GbR
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Germany (DE)
Zentrum für Gastroenterologie Saar MVZ GmbH
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Media Seasons - Steffen Kleinke & Ronny Burkersroda GbR
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
How to cite
APA:
Bokemeyer, B., Plachta-Danielzik, S., di Giuseppe, R., Efken, P., Mohl, W., Hoffstadt, M.,... Schreiber, S. (2024). Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study. Inflammatory Bowel Diseases, 30(5), 746-756. https://doi.org/10.1093/ibd/izad138
MLA:
Bokemeyer, Bernd, et al. "Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study." Inflammatory Bowel Diseases 30.5 (2024): 746-756.
BibTeX: Download